Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2016-06-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-15-0748PMID 27297869PMCID PMC4975650
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression

  2015cited by this paper
• IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway

  2015cited by this paper
• Duplex Ratio Tests as Diagnostic Biomarkers in Malignant Melanoma.

  2015cited by this paper
• Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.

  2015cited by this paper
• The phosphoinositide 3-kinase pathway and therapy resistance in cancer

  2015influential reference
• AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

  2015cited by this paper
• AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.

  2014cited by this paper
• Targeting Akt3 signaling in triple-negative breast cancer.

  2014cited by this paper
• PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting

  2014cited by this paper
• Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

  2014cited by this paper
• PTEN-deficient tumors depend on AKT2 for maintenance and survival.

  2014cited by this paper
• Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

  2014cited by this paper
• Insulin Receptor Substrate 2-mediated Phosphatidylinositol 3-kinase Signaling Selectively Inhibits Glycogen Synthase Kinase 3β to Regulate Aerobic Glycolysis*

  2014cited by this paper
• Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer

  2014influential reference
• Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer

  2013cited by this paper
• RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

  2013cited by this paper
• A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

  2013cited by this paper
• Droplet Digital™ PCR quantitation of HER2 expression in FFPE breast cancer samples.

  2013cited by this paper
• Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

  2013cited by this paper
• The genomic landscape of breast cancer as a therapeutic roadmap.

  2013cited by this paper
• The epigenetics of epithelial-mesenchymal plasticity in cancer

  2013cited by this paper
• Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.

  2013cited by this paper
• Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

  2013cited by this paper
• Development of PI3K inhibitors: lessons learned from early clinical trials

  2013cited by this paper
• Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

  2013cited by this paper
• K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo

  2012cited by this paper
• Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.

  2012cited by this paper
• The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

  2012cited by this paper
• Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

  2012cited by this paper
• Mechanisms of acquired resistance to targeted cancer therapies.

  2012cited by this paper
• Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and -independent mechanisms

  2011cited by this paper
• PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis

  2011cited by this paper
• PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

  2011cited by this paper
• Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib

  2011cited by this paper
• AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.

  2011cited by this paper
• Oncogenic PIK 3 CA-driven mammary tumors frequently recur via PI 3 K pathway – dependent and PI 3 K pathway – independent mechanisms

  2011cited by this paper
• First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

  2011cited by this paper
• Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance.

  2010cited by this paper
• Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.

  2010cited by this paper
• Molecular Predictors of 3D Morphogenesis by Breast Cancer Cell Lines in 3D Culture

  2010cited by this paper
• ALDH1 expression in human breast carcinoma.

  2009cited by this paper
• Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression.

  2009cited by this paper
• Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer.

  2009cited by this paper
• Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.

  2008cited by this paper
• Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.

  2007cited by this paper
• The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma

  2007cited by this paper
• Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma

  2007cited by this paper
• The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

  2006cited by this paper
• Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT.

  2005cited by this paper
• Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion.

  2004cited by this paper
• Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures.

  2003cited by this paper
• Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.

  2003cited by this paper
• Carcinoma Overexpression and Overactivation of Akt in Thyroid Updated

  2001cited by this paper
• Phosphoinositide 3-Kinase Binds Constitutively to α/β-Tubulin and Binds to γ-Tubulin in Response to Insulin (*)

  1995cited by this paper
• Phosphoinositide 3-kinase binds constitutively to alpha/beta-tubulin and binds to gamma-tubulin in response to insulin.

  1995cited by this paper

• Phosphorylation of plectin by Akt3 promotes triple-negative breast cancer cell invasive migration

  2025cites this paper
• AKT as a Therapeutic Target in Cancer.

  2025cites this paper
• Structural requirements of isoform-specific inhibitors of Akt: Implications in the development of effective cancer treatment strategies.

  2025cites this paper
• Live-Cell NanoBRET Assay to Measure AKT Inhibitor Binding to Conformational States of AKT

  2025influential citation
• Identification of Potential Breast Cancer Stem Cell Biomarkers in the Secretome Using a Network Interaction Approach Analysis

  2024cites this paper
• Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer

  2024cites this paper
• AKT kinases as therapeutic targets

  2024cites this paper
• AXL-TBK1 driven AKT3 activation promotes metastasis.

  2024cites this paper
• Combined treatment with ruxolitinib and MK-2206 inhibits ERα activity by inhibiting MAPK signaling in BT474 breast cancer cells

  2024cites this paper
• PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

  2023cites this paper
• Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy

  2023cites this paper
• Catalytic activity-modulated etching of plasmonic gold nanorods enabled ultra-sensitive colorimetric strategy for Early-Stage cancer diagnosis

  2023influential citation
• Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer.

  2023cites this paper
• Identify Gene-gene Regulatory Modules for Patients with Renal Clear Cell Tumor Metastasis

  2023cites this paper
• The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells

  2023cites this paper
• Circular RNAs with protein-coding ability in oncogenesis.

  2023cites this paper
• AKT Isoforms as a Target in Cancer and Immunotherapy.

  2022cites this paper
• Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells.

  2022cites this paper
• AXL-TBK1 driven nuclear AKT3 promotes metastasis

  2022cites this paper
• Overexpression of microRNA-145 enhanced docetaxel sensitivity in breast cancer cells via inactivation of protein kinase B gamma-mediated phosphoinositide 3-kinase -protein kinase B pathway

  2022cites this paper
• Upregulation of Receptor Tyrosine Kinase Activity and Stemness as Resistance Mechanisms to Akt Inhibitors in Breast Cancer

  2022cites this paper
• AKT3 is a key regulator of head and neck squamous cell carcinoma

  2021cites this paper
• CircRNA circTRAF3 promotes nasopharyngeal carcinoma metastasis through targeting miR-203a-3p/AKT3 axis.

  2021cites this paper
• High Expression MicroRNA-206 Inhibits the Growth of Tumor Cells in Human Malignant Fibrous Histiocytoma

  2021cites this paper
• Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition

  2021cites this paper
• Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy.

  2021cites this paper
• Emerging Roles for AKT Isoform Preference in Cancer Progression Pathways

  2021cites this paper
• High expression of long non-coding RNA Linc-A associates with poor survival in patients with colorectal cancer

  2020cites this paper
• Targeting Functional Activity of AKT Has Efficacy against Aggressive Neuroblastoma.

  2020cites this paper
• Effects of PKB/AKT inhibitors on insulin-stimulated lipogenesis and phosphorylation state of lipogenic enzymes in white adipose tissue.

  2020cites this paper
• Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer - A comprehensive review from chemotherapy to immunotherapy.

  2020cites this paper
• Precision Targeting of pten-Null Triple-Negative Breast Tumors Guided by Electrophilic Metabolite Sensing

  2020cites this paper
• Overexpression of Extradomain-B Fibronectin is Associated with Invasion of Breast Cancer Cells

  2020cites this paper
• The emerging role of BET inhibitors in breast cancer

  2020cites this paper
• Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling

  2019cites this paper
• Distinct functions of AKT isoforms in breast cancer: a comprehensive review

  2019cites this paper
• Targeting AKT for cancer therapy

  2019cites this paper
• Extradomain-B Fibronectin is a molecular marker of invasive breast cancer cells

  2019cites this paper
• Expression Levels of Therapeutic Targets as Indicators of Sensitivity to Targeted Therapeutics

  2019cites this paper
• Chemical Biology Gateways to Mapping Location, Association, and Pathway Responsivity

  2019cites this paper
• Quantitative Imaging of Morphometric and Metabolic Signatures Reveals Heterogeneity in Drug Response of Three-Dimensional Mammary Tumor Spheroids

  2019cites this paper
• Abstract. Phosphoprotein enriched in astrocytes 15 (PEA-15) plays an important role in controlling biological behaviors of cancer cells. In the present study, we demonstrated that PEA-15 was overexpressed in gastric cancer tissues and associated with tumor staging, differentiation, pathological type

  2019influential citation
• MicroRNA-433 targets AKT3 and inhibits cell proliferation and viability in breast cancer.

  2018cites this paper
• Short Communication: Updates on AKT Inhibition in Estrogen Receptor Positive Breast Cancer

  2018cites this paper
• An Akt3 Splice Variant Lacking the Serine 472 Phosphorylation Site Promotes Apoptosis and Suppresses Mammary Tumorigenesis.

  2018cites this paper
• Development and characterisation of a panel of phosphatidylinositide 3-kinase – mammalian target of rapamycin inhibitor resistant lung cancer cell lines

  2018cites this paper
• Ligand-based modeling of Akt3 lead to potent dual Akt1/Akt3 inhibitor.

  2018cites this paper
• Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases

  2017cites this paper
• miR-217 inhibits proliferation, migration, and invasion via targeting AKT3 in thyroid cancer.

  2017cites this paper
• BET inhibitors as novel therapeutic agents in breast cancer

  2017cites this paper
• Identification of Significant Pathways Induced by PAX5 Haploinsufficiency Based on Protein-Protein Interaction Networks and Cluster Analysis in Raji Cell Line

  2017cites this paper
• Protein Kinase Targets in Breast Cancer

  2017influential citation
• The LINK-A lncRNA interacts with PI(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors

  2017cites this paper
• Differential control of ageing and lifespan by isoforms and splice variants across the mTOR network.

  2017cites this paper
• Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells

  2017cites this paper